bortezomib 3.5 mg/1
bortezomib · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · Hikma Pharmaceuticals USA Inc.
Bortezomib is a proteasome inhibitor injection used to treat multiple myeloma and certain types of lymphoma by slowing or stopping cancer cell growth. It is administered intravenously by a healthcare provider as part of your cancer treatment plan.
Key Facts
- Brand Name
- bortezomib
- Generic Name
- bortezomib
- NDC Code (Product)
0143-9098- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Strength
- 3.5 mg/1
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS, SUBCUTANEOUS
- Marketing Status
- Application #
- ANDA215011
- Drug Class
- Proteasome Inhibitor [EPC]
- Marketing Start
- 07/27/2022
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is bortezomib used for?
Bortezomib is a proteasome inhibitor injection used to treat multiple myeloma and certain types of lymphoma by slowing or stopping cancer cell growth. It is administered intravenously by a healthcare provider as part of your cancer treatment plan.
Is bortezomib a controlled substance?
bortezomib is not classified as a controlled substance by the DEA.
What is the generic name for bortezomib?
The generic name for bortezomib is bortezomib. There are 11 other brand versions of bortezomib.
What is the NDC code for bortezomib 3.5 mg/1?
The NDC (National Drug Code) for bortezomib 3.5 mg/1 is 0143-9098, listed by Hikma Pharmaceuticals USA Inc..